Recorded Presentations from the NCCN 2026 Nursing Program: Advancing Oncology Nursing™

The NCCN 2026 Nursing Program: Advancing Oncology Nursing™ will equip you with timely updates in cancer treatment and supportive care. The sessions address the expanding role of nurses in areas such as early-phase clinical trial participation, therapeutic administration, radiation guidance, and perioperative care. In addition, the program explores strategies for addressing social determinants of health, enhancing symptom management, and facilitating difficult patient conversations with compassion and confidence.

By engaging in case-based learning and expert-led sessions, you will strengthen your clinical decision-making and patient advocacy skills, ultimately improving outcomes and quality of life for people with cancer.

Target Audience

This program is designed to meet the educational needs of oncology nurses who treat people with cancer.

Learning Objectives

The goal of the NCCN 2026 Nursing Program is to ensure that oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to:

Discuss advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology and apply appropriate treatment and supportive care strategies to optimize patient education and care.
Assess and address the physical, emotional, and social needs of patients with cancer through comprehensive symptom management, psychosocial screening, and survivorship planning.
Demonstrate effective communication, clinical judgement, and interdisciplinary collaboration to enhance nursing practice and patient safety in the cancer care environment.

Click here to view individual session learning objectives.

Additional information

Supporters:

This activity is supported by educational grants from:

AstraZeneca
Ipsen Biopharmaceuticals, Inc.
Novartis

This activity is supported through independent educational grants from:

Merck & Co., Inc., Rahway, NJ, USA
Regeneron Pharmaceuticals, Inc.

Supported by a grant from Pfizer Inc.

This educational activity is supported by an independent medical education grant from GSK.

Course summary

Course opens:

06/15/2026

Course expires:

03/01/2027

Cost:

$50.00

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Lorena Delgado, RN, MSN, OCN
Megan Hunter, BSN, RN, CCRN
Rochelle Jackson, DNP, APRN, FNP-C
Justin T. Kelly, MHI, BSN, RN, CCRN, RHIA, CL IV
Deborah Lundquist, PhD, RN
Molly Nestor, MSN, FNP-C, AOCNP
Heather O’Neal, MHI, BSN, RN, OCN
Carey Ramirez, DNP, ANP-C, ACHPN
Johanna Rochat, BSN, RN, OCN
Amanda E. Visnick, RN, BSN, OCN (Nursing Program Moderator)

The faculty listed below have the following relevant financial relationship with an ineligible company to disclose. All of the relevant financial relationships listed for this individual have been mitigated.

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

These activities are approved for nursing contact hours. Select sessions offer pharmacotherapeutic contact hours.

Complete accreditation information is included in each individual educational activity.

Status

Price

Title

Locked

$50.00Included

Recorded Presentations from the NCCN 2026 Nursing Program: Advancing Oncology Nursing™